Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome

BEDFORD, Mass.--(BUSINESS WIRE)--Mar. 25, 2024-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials